Karolinska Institutet (KI), founded in 1810 and is Sweden’s only university with a specific focus on biomedical sciences. In addition, KI annually awards the Nobel Prize in Physiology or Medicine. KI ranks as one of the world’s leading medical universities, thanks in part to the quality of its research activities, which today account for 40 per cent of all medical research carried out in Sweden.
KI has around 4 200 employees (FTEs), nearly two-thirds of whom are female. Some 80 per cent of KI’s income is devoted to research, distributed among some 600 research groups covering all medical fields. KI provides excellent postgraduate training with 2100 registered PhD students from around the world who are active in both basic and clinical research.
Research at KI has a strong European dimension, with almost 200 project participations within the EU’s now closed Sixth Framework Programme (FP6). Of these, KI coordinated 28 projects. KI is a major player in FP7, participating in some 323 projects, including 36 as coordinator as well as 31 European Research Council Grants. KI is also a major European beneficiary of funds from the National Institutes of Health in the U.S.
Role in project:
Evaluation of the economic impact of the innovative care pathway (WP8):
- Protocol & data collection tools
- Ethical review
- Data collection: from patients and from the pilot
- Development & estimation of models; analysis
KI’s activities in INNOVCare are co-funded by